<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04469998</url>
  </required_header>
  <id_info>
    <org_study_id>AXR201901</org_study_id>
    <nct_id>NCT04469998</nct_id>
  </id_info>
  <brief_title>Evaluation of AXR-270 for the Treatment of Posterior Blepharitis Associated With Meibomian Gland Dysfunction</brief_title>
  <official_title>A Phase I/II, Randomized, Double-Masked, Vehicle-Controlled Study of the Safety, Tolerability, and Efficacy of AXR-270 Topical Eyelid Cream in Treating Posterior Blepharitis Associated With Meibomian Gland Dysfunction</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AxeroVision, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AxeroVision, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will evaluate the safety, tolerability and efficacy of AXR-270 Cream in treating&#xD;
      posterior blepharitis associated with Meibomian Gland Disease (MGD)&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      AXR201901 is a multicenter, randomized, double-masked, vehicle-controlled study of AXR-270&#xD;
      cream and AXR-270 vehicle in subjects with signs and symptoms of posterior blepharitis&#xD;
      associated with meibomian gland dysfunction&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 16, 2020</start_date>
  <completion_date type="Actual">December 31, 2020</completion_date>
  <primary_completion_date type="Actual">December 1, 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Adverse Events</measure>
    <time_frame>22 Days</time_frame>
    <description>Incidence of ocular and systemic adverse events</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Total Meibomian Gland Dysfunction Score</measure>
    <time_frame>22 Days</time_frame>
    <description>Change from Baseline in total MGD score</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">129</enrollment>
  <condition>Posterior Blepharitis</condition>
  <condition>Meibomian Gland Dysfunction</condition>
  <arm_group>
    <arm_group_label>AXR-270 Low Dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>AXR-270 Low Dose administered once daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>AXR-270 High Dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>AXR-270 High Dose administered once daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>AXR-270 Vehicle</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>AXR-270 Vehicle administered once daily</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AXR-270 Low Dose</intervention_name>
    <description>AXR-270 Topical Eyelid Cream</description>
    <arm_group_label>AXR-270 Low Dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AXR-270 High Dose</intervention_name>
    <description>AXR-270 Topical Eyelid Cream</description>
    <arm_group_label>AXR-270 High Dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AXR-270 Vehicle</intervention_name>
    <description>AXR-270 Topical Eyelid Cream Vehicle</description>
    <arm_group_label>AXR-270 Vehicle</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Male or female, 18 years or older&#xD;
&#xD;
        Have a clinical diagnosis of moderate to severe MGD&#xD;
&#xD;
        Have a score of â‰¥35 on Eye Discomfort using VAS&#xD;
&#xD;
        Have a tFCS score between 3 and 14 on the NEI scale&#xD;
&#xD;
        Have a Schirmer score of &gt;7 mm&#xD;
&#xD;
        Have a OSDI score &gt;30&#xD;
&#xD;
        If female, then subject should be non-pregnant and non-lactating&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Subjects with iritis, uveitis, conjunctivitis, keratitis&#xD;
&#xD;
        Subjects with lid abnormalities&#xD;
&#xD;
        Subjects unable or unwilling to withhold the use of eyelid scrubs&#xD;
&#xD;
        Subjects with glaucoma and serious systemic disease&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>100 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Houman D Hemmati, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>AxeroVision, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>AxeroVision, Inc.</name>
      <address>
        <city>Carlsbad</city>
        <state>California</state>
        <zip>92008</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2020</verification_date>
  <study_first_submitted>July 9, 2020</study_first_submitted>
  <study_first_submitted_qc>July 13, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">July 14, 2020</study_first_posted>
  <last_update_submitted>January 12, 2021</last_update_submitted>
  <last_update_submitted_qc>January 12, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 13, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Meibomian Gland Dysfunction</keyword>
  <keyword>Posterior Blepharitis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Meibomian Gland Dysfunction</mesh_term>
    <mesh_term>Blepharitis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

